

Jynneos Vaccine EXAMPLE Competency Exam

The following questions pertain to the Jynneos vaccine (see [EUA](#) and [CDC Interim Clinical Considerations](#)):

1. This vaccine is authorized for use in which of the following age groups for the primary series?
 - a. 6 months – 5 years
 - b. 6 – 11 years
 - c. 12 years & older
 - d. 18 years & older
 - e. All ages

2. Patients ≥ 18 years of age should preferably receive _____ 4 weeks apart (alternative regimen).
 - a. 2-doses (0.5mL each) subcutaneously
 - b. 2-doses (0.1mL each) intradermally
 - c. 2-doses (0.5mL each) intramuscularly
 - d. All of the above are correct

3. Patients <18 years of age should receive _____ 4 weeks apart (standard regimen).
 - a. 2-doses (0.5mL each) subcutaneously
 - b. 2-doses (0.1mL each) intradermally
 - c. 2-doses (0.5mL each) intramuscularly
 - d. All of the above are correct

4. Unpunctured vials can be safely stored under the following conditions:
 - a. Ultra-cold (-90°C to -60°C) up to the expiration date found on the carton
 - b. Freezer (-25°C to -15°C) for up to the expiration date found on the carton
 - c. Refrigerator (2°C to 8°C) for up to 8 weeks
 - d. Both (b) & (c) are correct

5. After the first dose has been drawn, the vial should be stored between _____ and discarded after _____.
 - a. -25°C to -15°C ; 6 hours
 - b. 2°C to 8°C ; 8 hours
 - c. 2°C to 25°C ; 6 hours
 - d. 2°C to 25°C ; 12 hours

6. Jynneos vaccine initiated within 4 days of mpox exposure may provide the best chance to:
 - a. Prevent onset of the disease
 - b. Reduce severity after onset of infection
 - c. No benefit is expected

7. Jynneos vaccine initiated between 4 days to 14 days after exposure to mpox may potentially be:
 - a. More effective at preventing infection
 - b. No benefit is expected
 - c. May increase disease severity
 - d. Less effective at preventing infection, but may reduce severity of disease expected

8. True/False Limited supply of Jynneos is available in the U.S.; therefore, it is important to follow current guidance on at-risk populations and CDC and ACIP guidance on indications, as Jynneos is not recommended for the general population.

9. True/False This vaccine must be diluted prior to administration.

10. True/False Given the unknown effectiveness of vaccination in this outbreak, people who are vaccinated should continue to take steps to protect themselves from infection by avoiding close, skin-to-skin contact, including intimate contact, with someone who has mpox.

11. True/False Before drawing up a dose of the vaccine, vigorously shake the vial to properly mix the product.

12. True/False Each vial contains one dose for subcutaneous or up to 5 doses for intradermal injections.

13. True/False Persons of all ages with history of developing keloid scars should receive the standard vaccine regimen of 0.5mL subcutaneously.

14. True/False Intradermal administration should result in a wheal (pale bubble) forming under the skin.

15. True/False This vaccine is a live-attenuated virus vaccine, but it is also non-replicating (unlike other live-attenuated virus vaccines). As such, JYNNEOS is considered safe to administer in persons who are immunocompromised.

Vaccine Provider's Printed Name

Signature

Date